Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products

Eric P. Velazquez, Bradley S. Miller, Kevin C.J. Yuen

Research output: Contribution to journalReview articlepeer-review


Introduction: Somatrogon (NGENLA™) is a long-acting GH (LAGH) formulation that was approved in Canada in October 2021 for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon has also received approval in Australia, Japan, the European Union, the USA, and the UK. Somatrogon is a glycoprotein that utilizes three copies of the C-terminal peptide of human chorionic gonadotropin to delay its clearance allowing for once-weekly administration. Areas covered: The purpose of this article is to describe the development of somatrogon for treatment of individuals with GHD. Trials of somatrogon demonstrated positive efficacy results in adults (Phase 2) and children (Phase 2 and 3) with GHD including non-inferiority of height velocity compared to daily GH, with no concerning side effects. Growth responses, pharmacodynamics and safety data are compared to other LAGH products, lonapegsomatropin and somapacitan, in Phase 3 trials in pediatric GHD. Expert opinion: New LAGH products, including somatrogon, have the potential to increase patient adherence as well as improve quality of life and clinical outcomes. Clinicians will need to identify the best candidates for LAGH therapy and understand how to safely monitor and adjust therapy. Long-term surveillance studies are necessary to demonstrate adherence, efficacy, cost-effectiveness, and safety of LAGH preparations.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalExpert Review of Endocrinology and Metabolism
Issue number1
StatePublished - 2024

Bibliographical note

Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.


  • Growth
  • growth hormone deficiency
  • IGF-I
  • long-acting growth hormone
  • pediatric
  • somatrogon

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products'. Together they form a unique fingerprint.

Cite this